Bublot M, Pritchard N, Le Gros F-X, Goutebroze S
Biological Research and Development, Merial S.A.S., F-69007 Lyon, France.
J Comp Pathol. 2007 Jul;137 Suppl 1:S81-4. doi: 10.1016/j.jcpa.2007.04.017. Epub 2007 Jun 8.
Interference by maternally derived antibody (MDA) is a major problem for the vaccination of young chickens against infectious bursal disease (IBD). The choice of the timing of vaccination and of the type (degree of attenuation) of modified-live vaccine (MLV) to use is often difficult. An IBD vectored vaccine (vHVT13), in which turkey herpesvirus (HVT) is used as the vector, was recently developed. This vaccine is administered once at the hatchery, either in ovo or by the subcutaneous route, to 1-day-old chicks at a time when MDA is maximal. In terms of safety, the vHVT13 vaccine had negligible impact on the bursa of Fabricius when compared with classical IBD MLV. Vaccination and challenge studies demonstrated that this vaccine is able to protect chickens against various IBD virus (IBDV) challenge strains including very virulent, classical, and USA variant IBDV, despite the presence of high-titred IBD MDA at the time of vaccination. These data show that the vector vaccine combines a safety and efficacy profile that cannot be achieved with classical IBD vaccines.
母源抗体（MDA）的干扰是幼雏接种传染性法氏囊病（IBD）疫苗时的一个主要问题。选择疫苗接种时间和所用改良活疫苗（MLV）的类型（减毒程度）往往很困难。最近开发了一种以传染性法氏囊病为载体的疫苗（vHVT13），其中火鸡疱疹病毒（HVT）用作载体。这种疫苗在孵化场对1日龄雏鸡进行一次接种，可在卵内或通过皮下途径接种，此时MDA含量最高。在安全性方面，与经典的IBD MLV相比，vHVT13疫苗对法氏囊的影响可忽略不计。疫苗接种和攻毒研究表明，尽管接种疫苗时存在高滴度的IBD MDA，但这种疫苗能够保护鸡免受各种传染性法氏囊病病毒（IBDV）攻毒株的侵害，包括超强毒、经典和美国变异IBDV。这些数据表明，载体疫苗结合了经典IBD疫苗无法实现的安全性和有效性。
